拜卡林通过调节Nrf2-依赖的信号通路来改善异二醇诱导的心脏重塑
Kai Qian1,2, Li Song3, Jia-Min Guo4
1Department of Cardiology, Key Laboratory of Panvascular Diseases of Wenzhou, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325027, China. qqkkqian@126.com.
BMC cardiovascular disorders
|December 20, 2024
概括
拜卡林 (Bai) 通过激活Nrf2/HO-1通路,防止异二醇诱导的心脏损伤. 这种天然化合物可以缓解心脏损伤,并保持小鼠的心脏功能.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
- 生物化学 生物化学
背景情况:
- 心血管疾病是死亡的主要原因,药物治疗有限.
- 巴伊卡林 (Bai) 具有抗炎和抗氧化特性,表明潜在的心脏保护作用.
- 在异二醇 (ISO) 诱导的小鼠心脏损伤模型中研究Bai的疗效.
研究的目的:
- 评估Baicalin (Bai) 对小鼠因异二醇 (ISO) 引起的心脏损伤的心脏保护作用.
- 阐明潜在的分子机制,特别是Nrf2信号通路的作用.
主要方法:
- 在小鼠中使用腹膜内注射异二醇 (ISO) 诱导心脏损伤14天.
- 进行了组织病理学分析 (H&E,马森三色) 和心声回声学.
- 在体内和体外评估了Nrf2信号通路,并使用ML385.5进行了抑制研究.
主要成果:
- 拜卡林 (Bai) 在小鼠心脏组织中显著缓解了ISO诱导的病理变化和心肌缩.
- 心声扫描证实,在ISO治疗的小鼠中,Bai保留了心脏功能.
- 巴伊激活了Nrf2信号通路,而ML385对该通路的抑制阻断了巴伊的心脏保护作用.
结论:
- 拜卡林 (Bai) 显示出显著的心脏保护作用,防止异二醇诱导的心脏损伤.
- 该机制涉及Nrf2/HO-1信号通路的激活.
- 白调节心脏铁亡并改善心脏重塑,提供一种潜在的治疗策略.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
382
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
382
Heart Failure Drugs: β-Blockers
315
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
315
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
405
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
405
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
528
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
528
Heart Failure Drugs: Inotropic Agents
516
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
516


